MedPath

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

Phase 3
Completed
Conditions
HIV Infections
Registration Number
NCT00002224
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

Didanosine is an effective anti-HIV drug, but it can cause stomach upset. This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach more easily and hopefully will prevent stomach upset. The purpose of this study is to compare the effectiveness of ddI EC versus the standard form of ddI. Both forms of ddI will be given with stavudine (d4T) plus nelfinavir (NLF).

Detailed Description

Patients are randomized to 1 of 2 open-label treatment groups. Group 1 receives ddI EC plus d4T plus NLF for 48 weeks. Group 2 receives ddI plus d4T plus NLF for 48 weeks. Both forms of ddI are administered orally once daily. Antiviral activity is determined by the magnitude and the duration of reduction of plasma HIV RNA from baseline through Week 24.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (23)

Sorra Research Ctr / Med Forum

🇺🇸

Birmingham, Alabama, United States

AIDS Healthcare Foundation

🇺🇸

Los Angeles, California, United States

Robert Scott MD

🇺🇸

Oakland, California, United States

Beacon Clinic / Boulder Community Hosp

🇺🇸

Boulder, Colorado, United States

Community Health Care

🇺🇸

Fort Lauderdale, Florida, United States

Immunity Care and Research Inc

🇺🇸

Fort Lauderdale, Florida, United States

HIV Clinical Research Ctr

🇺🇸

Fort Lauderdale, Florida, United States

South Shore Hosp

🇺🇸

Miami, Florida, United States

Saint Josephs Comprehensive Research Institute

🇺🇸

Tampa, Florida, United States

AIDS Research Consortium of Atlanta

🇺🇸

Atlanta, Georgia, United States

Scroll for more (13 remaining)
Sorra Research Ctr / Med Forum
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.